MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma (L39594) - R8 - Effective August 18, 2024

Date Posted: October 9, 2025

This MolDX Local Coverage Determination (LCD) has been revised under contract numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY).

Effective Date: August 18, 2024

Summary of Changes:

Under Issue - Explanation of Change Between Proposed LCD and Final LCD: Added "The final LCD was modified to reflect new evidence received during the Comment period." Under Summary of Evidence: Table 2: Proposed Risk-Aligned Management Plans within the NCCN Guidelines Framework: Formatting, punctuation, and typographical errors were corrected. Under Summary of Evidence: Table 3: GEP Test Results That May Impact Decisions on Follow-up and Surveillance Intensity During the First Two Years after Diagnosis (Adapted from Arron et al 71). Reference number was corrected to "71."

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCD or access it via the CMS Medicare Coverage Database (MCD).

Last Updated Oct 09 , 2025